|
Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI). |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Pfizer |
Speakers' Bureau - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Research Funding - Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Pfizer |
Speakers' Bureau - GlaxoSmithKline; Novartis; Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
Aranzazu Gonzalez del Alba |
Consulting or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Janssen Oncology; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; PFIZER |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Janssen; Novartis |
|
Jose-Luis Gonzalez-Larriba |
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; GlaxoSmithKline; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Research Funding - GlaxoSmithKline (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer |